In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of TG Therapeutics Inc (NASDAQ: TGTX) closed at $36.66 in the last session, up 0.27% from day before closing price of $36.56. In other words, the price has increased by $0.27 from its previous closing price. On the day, 1.39 million shares were traded. TGTX stock price reached its highest trading level at $36.92 during the session, while it also had its lowest trading level at $36.03.
Ratios:
We take a closer look at TGTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.86. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.91.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.
Goldman Upgraded its Sell to Neutral on August 02, 2023, whereas the target price for the stock was revised from $16 to $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 11 ’25 when Lonial Sagar sold 20,852 shares for $32.24 per share. The transaction valued at 672,268 led to the insider holds 94,061 shares of the business.
Lonial Sagar bought 20,852 shares of TGTX for $672,233 on Sep 11 ’25. On Jun 13 ’25, another insider, Echelard Yann, who serves as the Director of the company, sold 10,000 shares for $36.94 each. As a result, the insider received 369,400 and left with 228,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5816681472 and an Enterprise Value of 5351185408. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 97.97, and their Forward P/E ratio for the next fiscal year is 20.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.67. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.81 while its Price-to-Book (P/B) ratio in mrq is 20.96. Its current Enterprise Value per Revenue stands at 11.785 whereas that against EBITDA is 62.304.
Stock Price History:
The Beta on a monthly basis for TGTX is 1.96, which has changed by 0.64912283 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $21.16. The 50-Day Moving Average of the stock is 15.76%, while the 200-Day Moving Average is calculated to be 6.34%.
Shares Statistics:
According to the various share statistics, TGTX traded on average about 2.19M shares per day over the past 3-months and 2022100 shares per day over the past 10 days. A total of 158.03M shares are outstanding, with a floating share count of 142.93M. Insiders hold about 9.92% of the company’s shares, while institutions hold 64.25% stake in the company. Shares short for TGTX as of 1757894400 were 24587257 with a Short Ratio of 11.21, compared to 1755216000 on 23538832. Therefore, it implies a Short% of Shares Outstanding of 24587257 and a Short% of Float of 20.27.
Earnings Estimates
Currently, 5.0 analysts are dedicated to thoroughly evaluating and rating the performance of TG Therapeutics Inc (TGTX) in the stock market.The consensus estimate for the next quarter is $0.31, with high estimates of $0.43 and low estimates of $0.21.
Analysts are recommending an EPS of between $0.96 and $0.53 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is $1.8, with 5.0 analysts recommending between $2.49 and $1.04.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $152.11M. It ranges from a high estimate of $155M to a low estimate of $150M. As of. The current estimate, TG Therapeutics Inc’s year-ago sales were $83.88MFor the next quarter, 6 analysts are estimating revenue of $173.5M. There is a high estimate of $178.39M for the next quarter, whereas the lowest estimate is $170.4M.
A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $591.84M, while the lowest revenue estimate was $582.8M, resulting in an average revenue estimate of $587.8M. In the same quarter a year ago, actual revenue was $329MBased on 7 analysts’ estimates, the company’s revenue will be $843.35M in the next fiscal year. The high estimate is $927M and the low estimate is $692.6M.
